Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply

N Engl J Med. 2019 Jun 13;380(24):2382. doi: 10.1056/NEJMc1903943.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Camptothecin / analogs & derivatives
  • Humans
  • Immunoconjugates*
  • Triple Negative Breast Neoplasms*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoconjugates
  • sacituzumab govitecan
  • Camptothecin